FDA Approves New Blood-Based Screening Test for Colorectal Cancer

The U.S. Food and Drug Administration (FDA) has approved SimpleScreen™ CRC, a new blood-based screening option for colorectal cancer in adults aged 45 and older who are at average risk for the disease. Abbott will commercialize the test in the U.S. this fall. The approval is based on the PREEMPT CRC study, the largest prospective clinical validation study for a blood-based colorectal cancer screening test, which enrolled over 48,000 adults. The test detected colorectal cancer with 81.1% sensitivity and showed 90.4% specificity for advanced colorectal neoplasia.

Context

Colorectal cancer is one of the leading causes of cancer-related deaths in the United States. Current screening methods primarily include colonoscopy and stool-based tests, which can be invasive or less appealing to some patients. The PREEMPT CRC study, which led to the test's approval, involved over 48,000 participants, making it a robust validation of the test's effectiveness.

Why it matters

The FDA's approval of SimpleScreen™ CRC represents a significant advancement in colorectal cancer screening, offering a non-invasive option for adults at average risk. Early detection of colorectal cancer can lead to better treatment outcomes and potentially save lives. This test may increase screening rates among individuals who are hesitant to undergo traditional procedures like colonoscopies.

Implications

The introduction of this blood-based test could change the landscape of colorectal cancer screening, potentially leading to earlier diagnoses. Patients who previously avoided screening may be more inclined to participate due to the less invasive nature of the test. If successful, this could result in improved public health outcomes and a reduction in colorectal cancer mortality rates.

What to watch

Abbott plans to launch SimpleScreen™ CRC in the U.S. this fall, and its availability could influence screening practices. Healthcare providers may begin integrating this test into routine screenings for eligible patients. Monitoring the uptake of this test and its impact on screening rates will be important in the coming months.